Breaking News, Trials & Filings

Hospira Presents Results for Remicade Biosimilar

Open-label studies of Inflectra shows similarity

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Hospira has posted the results of two open-label extension studies of CT-P13 (infliximab), one in patients with rheumatoid arthritis, the other in patients with ankylosing spondylitis. The results were presented at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Diego. CT-P13, branded as Inflectra, was approved by the EMA in September 2013 as a biosimilar to reference product, Remicade (infliximab). Inflectra is not c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters